rhIL-7-hyFc enhances re-expansion and anti-myeloma efficacy of BCMA CAR-iNKTs in vivo. (A) The 7 rhIL-7-hyFc–treated tumor-free mice at the end of the experiment shown in Figure 2C (BCMA⁺ rh-IL7-hyFc) were subjected to re-challenge with MM.1S-CG cells and treated with vehicle or again with hIL-7-hyFc (10 mg/kg subcutaneously, the day of MM.1S-CG infusion and, again, 1 week later). Normalized BLI images of MM.1S-CG re-challenged mice. (B) Quantitation of BLI signal in each mouse. (C) Kaplan-Meier survival analysis. (D) Absolute numbers of BCMA CAR-iNKTs per μL blood (CD45 CD3 Vα24-Jα18 CD34) in re-challenged mice.